MicroRNA Biomarkers in Lung Cancer Management

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play critical roles in lung tumour development, progression and response to therapy. Aberrant miRNA expression profiles have been detected in tumour tissue, circulating blood and exosomes, providing minimally invasive windows into tumour biology. Panels of specific miRNAs can discriminate between malignant and benign nodules, predict risk of relapse and monitor treatment response. Advances in high-throughput sequencing, digital PCR and machine-learning-driven signature selection have accelerated the translation of miRNA biomarkers into clinical workflows. Despite challenges in assay standardisation, pre-analytical variability and heterogeneity across tumour subtypes, integration of miRNA panels with imaging and established protein markers is paving the way for precision screening, prognostic stratification and adaptive therapy in both non-small cell and small cell lung cancer.

Research from Nature Portfolio

Recent studies have harnessed large patient cohorts and cutting-edge technologies to refine circulating miRNA signatures for early detection. One report described a multiplexed droplet digital PCR assay capable of quantifying a defined set of plasma miRNAs with high precision and low inter-assay variability, demonstrating utility in distinguishing stage I non-small cell lung cancer (NSCLC) from matched controls and predicting postoperative relapse. Another investigation integrated small-RNA sequencing with machine learning to derive a blood-based miRNA classifier that achieved sensitivity above 90 per cent for stage I tumours and maintained robust performance across smoking histories and histological subtypes. A third study elucidated mechanistic links between hypoxia-regulated miR-210 and chemoresistance pathways in NSCLC, supporting the incorporation of functional miRNA markers into prognostic panels and highlighting miRNA modulation as a therapeutic adjunct.

MicroRNA Biomarkers in Lung Cancer Management publication trend

The graph below shows the total number of articles in microrna biomarkers in lung cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): A small (19–25 nucleotide) non-coding RNA that regulates gene expression post-transcriptionally by binding target messenger RNAs.

Biomarker: A measurable molecular indicator of a biological state, here used for diagnosis, prognosis or prediction of treatment response in lung cancer.

Non-small cell lung cancer (NSCLC): The most common lung cancer subtype, comprising adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

Droplet digital PCR (ddPCR): A highly sensitive method for absolute quantification of nucleic acids by partitioning samples into thousands of droplets and performing end-point PCR.

Circulating miRNA: miRNA molecules found in blood plasma or serum, often encapsulated within exosomes or bound to proteins, serving as non-invasive tumour biomarkers.

References

1. MicroRNAs in metabolism for precision treatment of lung cancer. Cellular & Molecular Biology Letters (2024).
2. Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review. Cancer Cell International (2023).
3. Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC. PLOS ONE (2013).